DoD expert to speak about chemical, biological threats at upcoming summit
LONDON March 13, 2017 Dr Allison Hinds, part of the chemical/biological warfare in public heath and infectious disease division for the Department of Defense, will be joining pharmaceutical R&D professionals at the CRISPR Summit this May. Her role within the department is to provide technical advice and strategic operational recommendations pertaining to chemical and biological threats.
Dr Hinds will be discussing the ethical challenges and threats of gene editing technologies like the CRISPR/Cas 9 system. She will be sharing her expertise on what happens when gene editing tools become misused and what can happen when technologies are used for purposes that move away from research applications.
The CRISPR Summit is the most advanced in its coverage of the challenges surrounding the CRISPR/Cas9 system, giving attendees clarity as to how to improve their research and hear about how leaders of the pharma, biotech and academic industry have looked to address the key issues and fully unlock the potential
Joining Dr Hinds to address CRISPR's application challenges will be an expert panel of speakers including:
- Catherine Coombes, Senior Patent Attorney, HGF Limited
- Danilo Maddalo, Lab Head ONC Pharmacology, Novartis Institutes for BioMedical Research
- Ian Rosewell, Group Lead, The Francis Crick Institute
- Jenna Bradley, Senior Research Scientist in Cellular Reagents and Assay Development in Discovery Sciences, AstraZeneca
- Caroline Hill, Group Leader, The Francis Crick Institute
- Javier Terriente, CSO, ZeClinics
- Ping Zhang, Postdoctoral Scientist, Ludwig Institute for Cancer Research, University of Oxford
- Natalia Moncaut, Transgenic Production Facility Manager, Cancer Research UK Manchester Institute
The CRISPR Summit will be taking place in London on 17 - 18 May. Find the full programme and registrations details on http://www.crisprsummit.iqpc.co.uk, phone +44 (0)207 036 1300 or email [email protected]